{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"13.1","value":"7.5"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"8.4","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"Defined as the time from the date of randomization to the date of documented disease progression","dispersionType":"Inter-Quartile Range","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-PFS Population: Includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis","type":"SECONDARY","unitOfMeasure":"months"}